Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease

CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development Robust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study 1 Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest dose The safety and tolerability profile of diranersen was generally consistent with the Phase 1b study 1 CELIA is an 18-month Phase 2 randomized, placebo-controlled, dose-ranging study evaluating diranersen, a tau-targeting antisense oligonucleotide (ASO) Data will be presented at the Alzheimer’s Association International Conference (AAIC) 2026 and other upcoming scientific congresses

The release as fetched from its publisher. biogen.com ↗